logo
#

Latest news with #JonBerggren

Dynavox Group AB (DYVOX) Receives a Buy from Kepler Capital
Dynavox Group AB (DYVOX) Receives a Buy from Kepler Capital

Business Insider

time12-06-2025

  • Business
  • Business Insider

Dynavox Group AB (DYVOX) Receives a Buy from Kepler Capital

Kepler Capital analyst Jon Berggren maintained a Buy rating on Dynavox Group AB (DYVOX – Research Report) on June 10 and set a price target of SEK85.00. The company's shares closed last Tuesday at SEK108.80. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Berggren is a 4-star analyst with an average return of 9.3% and a 56.00% success rate. Berggren covers the Healthcare sector, focusing on stocks such as Swedish Orphan Biovitrum AB, Herantis Pharma, and Nightingale Health Oyj Class B. Currently, the analyst consensus on Dynavox Group AB is a Moderate Buy with an average price target of SEK85.00.

Kepler Capital Reaffirms Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)
Kepler Capital Reaffirms Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)

Business Insider

time06-06-2025

  • Business
  • Business Insider

Kepler Capital Reaffirms Their Buy Rating on Swedish Orphan Biovitrum AB (0MTD)

Kepler Capital analyst Jon Berggren maintained a Buy rating on Swedish Orphan Biovitrum AB (0MTD – Research Report) on June 4 and set a price target of SEK350.00. The company's shares closed last Wednesday at SEK303.25. Confident Investing Starts Here: Berggren covers the Healthcare sector, focusing on stocks such as Swedish Orphan Biovitrum AB, Herantis Pharma, and Nightingale Health Oyj Class B. According to TipRanks, Berggren has an average return of 9.5% and a 55.10% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Swedish Orphan Biovitrum AB with a SEK363.00 average price target. Based on Swedish Orphan Biovitrum AB's latest earnings release for the quarter ending March 30, the company reported a quarterly revenue of SEK6.47 billion and a net profit of SEK875 million. In comparison, last year the company earned a revenue of SEK6.26 billion and had a net profit of SEK800 million

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store